Tirzepatide vs Semaglutide: What the SURMOUNT-5 Trial Actually Tells Us

If you have been following the world of weight loss medications, you have probably seen the headlines. Tirzepatide beats semaglutide. The numbers are striking, the buzz is real, and a lot of people are left wondering which one is actually right for them. The SURMOUNT-5 trial gave us the most direct head-to-head data we have ever had, so let us break it down without the noise.

What SURMOUNT-5 Actually Compared

This trial put tirzepatide (sold as Mounjaro) up against semaglutide (Ozempic or Wegovy) in people with obesity or overweight who also had at least one related health condition. Nobody had diabetes. The study lasted 72 weeks, which is roughly a year and a half, and the goal was simple: see which medication produced more weight loss.

The results were significant. People taking tirzepatide lost around 47 pounds on average, while the semaglutide group lost about 27 pounds. That is nearly double. The percentage body weight loss followed the same pattern, with tirzepatide users reaching around 20 percent body weight reduction compared to roughly 13 percent for semaglutide.

It is worth noting that both groups also received lifestyle counseling, which matters. These medications do not work in a vacuum. Diet, movement, and behavior all play a role, and the trial design reflected that.

Why the Difference in Results

Tirzepatide works by mimicking two hormones, GLP-1 and GIP, while semaglutide only targets GLP-1. That second pathway, GIP, seems to add something meaningful to the equation. Think of it as having two keys unlocking the same door instead of one. The combined effect appears to create a stronger appetite suppression signal and better metabolic response.

That does not automatically make tirzepatide the winner for everyone. The second hormone also means a different side effect profile for some people. Nausea, digestive issues, and other common complaints showed up in both groups, but the pattern and intensity can vary from person to person.

Who Got the Best Results

The trial included a diverse group of participants, and the response was not uniform. Some people on semaglutide lost just as much weight as some people on tirzepatide. Genetics, baseline metabolism, how consistent someone was with the medication, diet choices, and physical activity levels all influenced outcomes.

Older participants and those with a longer history of obesity sometimes had more modest results, which is a pattern we see across most weight loss interventions. The body tends to adapt, and those adaptations vary by individual.

People who tracked their food intake, moved more, and used the medication as prescribed consistently outperformed those who did not. That part is not glamorous, but it is true.

What About Side Effects

Both medications share a similar side effect profile because they are in the same drug class. The most common issues involve the stomach and intestines, like nausea, vomiting, diarrhea, and constipation. Most of these are mild to moderate and tend to settle down as the body adjusts.

One thing worth mentioning is that tirzepatide showed slightly higher rates of nausea and vomiting in the trial. That does not mean it is harder to tolerate overall, just that the specific combination of effects can differ. Some people tolerate one better than the other, and it is hard to predict which will be gentler for any given person without trying it.

Rare but more serious concerns exist for both, including gallbladder problems and, in very rare cases, pancreatitis. These are not common, but they are worth discussing with a doctor before starting either medication.

Cost and Access

Price is a real factor for many people. Both medications are expensive without insurance coverage or manufacturer coupons. Availability also varies by region and pharmacy, and shortages have affected both at different times.

Checking your options through a prescription platform that compares pricing and checks insurance eligibility can save time and money. If you are serious about starting either one, it helps to do some homework on costs before your appointment so you can have an honest conversation with your provider.

Which One Should You Choose

There is no single correct answer here. The SURMOUNT-5 data gives tirzepatide the edge in average weight loss outcomes, but averages do not tell the whole story. Your health history, other conditions, how your body responds to medications, cost, and your personal goals all matter.

Some people feel better on semaglutide. Others get better results with tirzepatide. A healthcare provider who knows your full picture is the best person to help you decide. If you are not sure where to start, taking a short assessment can help clarify which option might align better with your situation before you book that appointment.

The Bottom Line

The SURMOUNT-5 trial gave us the clearest comparison yet between these two popular medications. Tirzepatide produced greater average weight loss in the study, but both led to meaningful improvements for most participants. The best choice depends on your body, your budget, and a conversation with your doctor.

Weight loss is personal, and what works brilliantly for one person may be just okay for another. Use the data as a starting point, not a final verdict. The right medication is the one you can stay on, tolerate well, and that fits your life. If you want help thinking through your options, take a look at this quiz that walks through your goals and preferences so you can go into your next appointment feeling more prepared.

Starting the conversation is often the hardest part. The research is on your side, and so is the possibility of feeling better.

References

• EMA — Mounjaro (tirzepatida), EPAR
• Jastreboff et al., SURMOUNT-1 — NEJM (2022)
• OMS — Obesity and overweight, fact sheet